Get the app
US › Healthcare

Danaher Corporation (DHR)

US · Healthcare · Diagnostics & Research

$229.04-1.06%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$6.26B
Revenue YoY
+5.5%
Net profit
$870.0M
Profit YoY
+56.8%
EPS
$1.94
EPS estimate
$1.84
Net margin
13.9%

EPS came in at 1.94 against a street estimate of 1.84 — a beat of 5.4%.

Key statistics

Market cap
$161.01B
P/E
40.8
Forward P/E
23.8
P/B
2.96
Book value
$74.81
EPS (TTM)
$5.61
Dividend yield
0.62%
52-week high
$241.35
52-week low
$160.31
50-day MA
$213.90
200-day MA
$201.32
Beta
0.80

Analyst view

Analysts rate Danaher Corporation a strong buy (22 buy, 3 hold, 0 sell out of 25) with an average price target of $244.14.

Shareholding

Insiders
10.82%
Institutions
84.23%

Largest institutional holders

FundStake
BlackRock Inc7.84%
Vanguard Capital Management, LLC5.89%
FMR Inc4.20%
State Street Corp4.05%
Wellington Management Company LLP2.32%
Capital Research & Mgmt Co - Division 32.21%
Geode Capital Management, LLC2.03%
Vanguard Portfolio Management, LLC2.02%

Recent filings & reports

DocumentDate
Board / officer change · Q4 2026
HEADLINE NUMBERS • Danaher increased its Board of Directors from 11 to 13 members on October 9, 2026. • Daniel L. Comas and Robert M. Hershberg, M.D
2026-10-13
Board / officer change · Q3 2026
DANAHER CORPORATION - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Julie Sawyer Montgomery appointed as President and CEO effective October 1, 2026,
2026-08-03
Quarterly report · Q2 2026
DANAHER CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month sales (ended June 26, 2026): $12,216 million vs. $11,677 million prior year
2026-07-21
Results announced · Q3 2026
DANAHER CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net earnings: $870 million, or $1.23 per diluted share, up 60% year-over-year • No
2026-07-21
Company announcement · Q2 2026
DANAHER CORPORATION - 8-K FILING SUMMARY HEADLINE NUMBERS • Total debt issuance: CHF 2,382,430,000 (~$2.6 billion USD equivalent) • Seven separate n
2026-06-03
Board / officer change · Q2 2026
DANAHER CORPORATION (DHR) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 5, 2026 • Omnibus Incentive Plan approved with 2
2026-05-07
Quarterly report · Q1 2026
DANAHER CORPORATION - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Sales: $5,951 million for Q1 2026 vs. $5,741 million for Q1 2025 (+3.7% year-ove
2026-04-21
Proxy statement · Q2 2026
DANAHER CORPORATION PROXY SUMMARY FOR RETAIL INVESTORS --- CEO TOTAL COMPENSATION & CHANGE Rainer M. Blair (President & CEO) 2025 Total Compensatio
2026-03-25

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.40 / share
ex-date Sep 30, 2026 · pay Oct 30, 2026
2026-09-30
Dividend$0.40 / share
ex-date Jun 26, 2026 · pay Jul 31, 2026
2026-06-26
Dividend$0.40 / share
ex-date Mar 27, 2026 · pay Apr 24, 2026
2026-03-27
Dividend$0.32 / share
ex-date Dec 26, 2025 · pay Jan 30, 2026
2025-12-26
Dividend$0.32 / share
ex-date Sep 26, 2025 · pay Oct 31, 2025
2025-09-26

Deals & corporate news

AnnouncementDate
CEO to comment on 2025 financial performance at healthcare conference
Danaher Corporation filed an 8-K on January 12, 2026, announcing that its CEO will comment on financial performance at the J.P. Morgan Healthcare Conference on January 13, 2026. The filing i
2026-01-12

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Danaher Corporation — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-18.